X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with AANJANEYA LIFECARE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs DR. DATSONS LABS - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA DR. DATSONS LABS ALEMBIC PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 29.0 -10.9 - View Chart
P/BV x 6.6 0.2 4,076.0% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ALEMBIC PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
DR. DATSONS LABS
Mar-14
ALEMBIC PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs792126 630.3%   
Low Rs44331 1,433.7%   
Sales per share (Unadj.) Rs167.0133.0 125.6%  
Earnings per share (Unadj.) Rs38.20.2 25,171.0%  
Cash flow per share (Unadj.) Rs42.06.6 635.5%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs84.9128.8 65.9%  
Shares outstanding (eoy) m188.5231.66 595.5%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x3.70.6 628.2%   
Avg P/E ratio x16.2516.1 3.1%  
P/CF ratio (eoy) x14.711.8 124.1%  
Price / Book Value ratio x7.30.6 1,196.8%  
Dividend payout %10.50-   
Avg Mkt Cap Rs m116,3832,477 4,697.8%   
No. of employees `000NANA-   
Total wages/salary Rs m4,21456 7,524.6%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m31,4874,211 747.8%  
Other income Rs m5579 70.0%   
Total revenues Rs m31,5424,289 735.4%   
Gross profit Rs m10,060569 1,769.2%  
Depreciation Rs m722204 353.3%   
Interest Rs m37430 8.6%   
Profit before tax Rs m9,35613 73,669.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m-2-2 83.3%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1606 35,413.1%   
Profit after tax Rs m7,1945 149,881.3%  
Gross profit margin %31.913.5 236.6%  
Effective tax rate %23.148.0 48.1%   
Net profit margin %22.80.1 20,042.3%  
BALANCE SHEET DATA
Current assets Rs m15,0666,852 219.9%   
Current liabilities Rs m7,6746,711 114.4%   
Net working cap to sales %23.53.3 701.0%  
Current ratio x2.01.0 192.3%  
Inventory Days Days67161 41.6%  
Debtors Days Days41318 12.8%  
Net fixed assets Rs m8,2373,673 224.3%   
Share capital Rs m377317 119.1%   
"Free" reserves Rs m15,4163,761 409.9%   
Net worth Rs m16,0054,078 392.5%   
Long term debt Rs m01,671 0.0%   
Total assets Rs m24,59412,633 194.7%  
Interest coverage x255.21.0 24,792.0%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.30.3 384.1%   
Return on assets %29.43.4 853.9%  
Return on equity %44.90.1 38,183.4%  
Return on capital %58.77.7 764.6%  
Exports to sales %55.722.9 243.5%   
Imports to sales %10.414.3 72.9%   
Exports (fob) Rs m17,551964 1,820.6%   
Imports (cif) Rs m3,283602 545.4%   
Fx inflow Rs m17,811964 1,847.6%   
Fx outflow Rs m5,318607 876.0%   
Net fx Rs m12,493357 3,500.3%   
CASH FLOW
From Operations Rs m9,3041,345 691.8%  
From Investments Rs m-3,105-2,256 137.6%  
From Financial Activity Rs m-1,959-1,200 163.3%  
Net Cashflow Rs m4,240-2,111 -200.9%  

Share Holding

Indian Promoters % 74.1 4.5 1,635.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 0.0 -  
FIIs % 9.1 1.4 674.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 94.1 14.8%  
Shareholders   49,328 20,807 237.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  MERCK LTD  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - SUVEN LIFE COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS